Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CerebraCell
- Development stage
- Unknown
- Lead developer
- Leonhardt Ventures
- Modality
- Device-based Delivery → Drug Delivery Systems, Stem Cell Therapies → Cell Therapies, Hydrogel Systems → Drug Delivery Systems, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Implant, Percutaneous
01
Overview
CerebraCell is a multi-modal regenerative therapy developed by Leonhardt Ventures for the treatment of various neurological disorders. The platform combines bioelectronic microcurrent stimulation with a proprietary 15-component biologic composition (referred to as CCA-15 or CCR-15) delivered via a programmable, refillable micro-infusion pump. The therapy's primary mechanism involves using specific bioelectric signals to upregulate the expression of stromal cell-derived factor 1 (SDF-1), which serves as a homing signal to recruit both endogenous and delivered stem cells to damaged brain tissue. The biologic component includes a mixture of stem cells, growth factors, exosomes, and a nutrient hydrogel designed to promote neurogenesis and angiogenesis. CerebraCell is being developed for a wide range of indications, including stroke recovery, traumatic brain injury, Parkinson's disease, Alzheimer's disease, and depression.
- Brand names
- CerebraCell
- Other names
- Leonhardt Ventures CerebraCell
Beyond the preview
Go deeper on CerebraCell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CerebraCell.